Homepage

Slug
/
Sections
Video
Video file
Video
Video file
Author Info

Deepak Sapra, 
CEO, API and Services

Video
Video file
Author Info

Phanimitra B,
Chief Information Officer

Video
Video file
Eyebrow
Leader’s POV
Headline Description

Our  approach to quality is rooted in science, using strong systems, skilled teams, and advanced automation to ensure excellence from development to manufacturing.

Research and Development

Slug
/research-and-development
Sections
Banner Image
Image
e22
Title
Our Capabilities
Number
8
Headline

Global R&D Sites across 4 countries

Countries
India
USA
Netherlands
UK
description

Our research sites host top scientific minds working to make health accessible worldwide.

Map Image
Image
47a
Stats
Stat value
R&D Scientists
Stat value
FTM launches in priority markets
Item
Headline

Our R&D Focus

description

At the core of our R&D prowess is the Integrated Product Development Organisation (IPDO), at Bachupally, Hyderabad, India. The expansive campus of IPDO houses several laboratories with the most recent being the Nutraceutical R&D centre. These labs, powered by a diverse talent pool of scientists from leading institutions around the world. \n\nOur product development efforts drive a portfolio of more than 1,000 products enabled by our robust R&D team consisting of more than 150 doctorates.

Headline

Future Focus

description

We run pioneering projects at the cutting edge of drug development across all technologies and dosage forms. Our team has expertise across therapeutic areas and geographies for generics as well as APIs, biosimilars, OTC drugs and other differentiated products.\n\nAlong with our deep and diverse expertise across chemistry, engineering, biology and formulations, we are also exploring advanced manufacturing technologies, measurement, analytics & controls, modelling & simulation and digital innovation.\n\nIn short, our R&D capabilities play a key role in fulfilling our promise of addressing unmet patient needs, bringing expensive medicines within reach and helping patients manage disease better.

Headline

Digital Science

description

Our Digital science initiative helps give impetus to our Research and Development effort with data and analytics use cases across the development cycle. These use cases are aimed at achieving significant reduction in drug development cycle time, improvement of bio study success rate, cost savings to enable First-to-Market products, accelerating the R&D timeline, etc.

Research and Development

Slug
/digitalisation
Sections
Banner Image
Image
key3
Title
Our Capabilities
Items
Title
Core Pharma Value Chain
Content
Title
Digital Science
description

Our Digital science initiative helps give impetus to our Research and Development effort with data and analytics use cases across the development cycle. These use cases are aimed at achieving significant reduction in drug development cycle time, improvement of bio study success rate, cost savings to enable First-to-Market products, accelerating the R&D timeline, etc.

Title
Operations
description

‘Digitalise the Core’ is our approach to simplifying and digitalising our processes. It is about creating scale without adding complexity.\n\nThe World Economic Forum has recognised our largest manufacturing facility in Bachupally, Hyderabad, as part of its Global Lighthouse Network.\n\nThe successful inclusion of our 25-year old site in Hyderabad as a ‘Digital Lighthouse’ factory is a big milestone in our productivity improvement journey. We have seen significant financial and operational impact from the journey (From 2017 to 2021, we have seen a 56% increase in our factory output and a 30% reduction in production lead time). We are in the process of scaling and replicating this to the rest of our manufacturing network. We aspire to be the most efficient pharma operations in the world. Our productivity improvement and digitalisation efforts are key to staying competitive, meeting business imperatives, and meeting our ambitious ESG goals.\n\nBuilding such ‘factories of the future’ is integral to innovation and to build healthcare of the future.\n\nWe began our digitalisation journey four years ago with an ambitious programme to digitise our core. This involved upgrade of infrastructure and digitisation of processes for robust and comprehensive data capture. Real-time data and insights laid the foundation for Project ‘OpsNext’ which was initiated two years ago to transform the plant into an Industry 4.0-driven ‘Lighthouse’ factory as defined by the WEF. The site saw the deployment of six of the eight technologies of 4IR – Advanced Analytics, Digital Twins, Robotic Process Automation, Augmented/Virtual/Mixed Reality, Digital Performance Management and Industrial Internet of Things (IIoT). The OpsNext team identified 40+ business results linked use cases impacting various aspects of productivity such as customer service, quality, energy consumption, sustainability, equipment efficiency and people productivity. The company also invested heavily in building people capabilities such as digital and analytics translators, data scientists and data engineers. Our DnA business translators have become experts at identifying what needs improvement in the physical world, taking it to the digital world, solving it in the digital world, and bringing those recommendations back into the physical world for implementation.\n\nOur smart autonomous factories, managed with data and machine learning, are lowering pharma manufacturing costs, improving quality and increasing productivity. As of October '22, our journey has already yielded significant results at the site – 43% manufacturing cost improvement, 30% reduction in production lead time, 41% energy consumption reduction, and significant dip in quality deviations.

Title
Patient & Customer Journey
Content
Title
Best in class knowledge sharing platforms for doctors
description

We have scaled up our digital efforts to provide better service to doctors using engagement platforms that provide all relevant information at a single place. We also use omni-channel methods to cover more doctors with the most relevant and personalised content. We have enabled our sales representatives in the field with advanced analytics-based algorithms for better efficiency, and relevant and personalised engagement with each doctor.  One such platform is DocVidya. DocVidya is a site for doctors based in India to engage them digitally; provide personalised content based on their specialty, interest areas and digital behaviour.\n\nIn July 2022, we launched Mederich for doctors in Brazil. The platform provides relevant , curated & unique scientific content  to HCPs to facilitate improved treatment outcomes for patients.\n\nOur multiple knowledge-sharing platforms across the globe, with content specially curated for the specific region – Betawissen (Germany), Medznat (Russia).

Title
Design
description

Patients are the core of everything that we do. Keeping them at the centre, we aspired to transform the patient healthcare experience. The goal being – applying principles of design thinking to every aspect and every stage of a patient’s healthcare experience and journey. Aligned to this goal, in 2015, we became an incubator for a small team of researchers, designers and thinkers. Thus, our design thinking arm, Studio 5b, was born.\n\nToday, it is home to some of the sharpest minds in the field of design, behavioural science, experience design, and research. Their goal: keeping the needs of the patient at the heart of every solution while designing healthcare touchpoints of the future.\n\nLearn more about Studio 5b.

Research and Development

Slug
/manufacturing-and-supply
Sections
Banner Image
Image
e22
Title
Our Capabilities
Number
8
Headline

Global R&D Sites across 4 countries

Countries
India
USA
Netherlands
UK
description

Our research sites host top scientific minds working to make health accessible worldwide.

Map Image
Image
47a
Stats
Stat value
Drug Master Files
Stat value
Reduced Energy Consumption
Stat value
Reduced Production Lead Time
Item
Headline

Smart Operations

description

The World Economic Forum has recognised our largest manufacturing facility in Bachupally, Hyderabad, as part of its Global Lighthouse Network.\n\nThe successful inclusion of our 25-year-old site in Hyderabad as a ‘Digital Lighthouse’ factory is a big milestone in our productivity improvement journey. We have seen significant financial and operational impact from the journey (From 2017 to 2021, we have seen a 56% increase in our factory output and a 30% reduction in production lead time). We are in the process of scaling and replicating this to the rest of our manufacturing network. We aspire to be the most efficient pharma operations in the world. Our productivity improvement and digitalisation efforts are key to staying competitive, meeting business imperatives, and meeting our ambitious ESG goals.\n\nBuilding such ‘factories of the future’ is integral to innovation and to build healthcare of the future.\n\nWe began our digitalisation journey four years ago with an ambitious programme to digitise our core. This involved upgrade of infrastructure and digitisation of processes for robust and comprehensive data capture. Real-time data and insights laid the foundation for Project ‘OpsNext’ which was initiated two years ago to transform the plant into an Industry 4.0-driven ‘Lighthouse’ factory as defined by the WEF. The site saw the deployment of six of the eight technologies of 4IR – Advanced Analytics, Digital Twins, Robotic Process Automation, Augmented/Virtual/Mixed Reality, Digital Performance Management and Industrial Internet of Things (IIoT). The OpsNext team identified 40+ business results linked use cases impacting various aspects of productivity such as customer service, quality, energy consumption, sustainability, equipment efficiency and people productivity. The company also invested heavily in building people capabilities such as digital and analytics translators, data scientists and data engineers. Our DnA business translators have become experts at identifying what needs improvement in the physical world, taking it to the digital world, solving it in the digital world, and bringing those recommendations back into the physical world for implementation. Our smart autonomous factories, managed with data and machine learning, are lowering pharma manufacturing costs, improving quality and increasing productivity.\n\nAs of October '22, our journey has already yielded significant results at the site – 43% manufacturing cost improvement, 30% reduction in production lead time, 41% energy consumption reduction, and significant dip in quality deviations.